logo
US-China trade talks: Can China reduce its export dependence?

US-China trade talks: Can China reduce its export dependence?

BEIJING (AP) — China's high dependence on exports will likely be a key focus of a new round of U.S.-China trade talks this coming week in Stockholm, but a trade deal would not necessarily help Beijing to rebalance its economy.
U.S. Treasury Secretary Scott Bessent has said he hopes the negotiations can take up this issue, along with China's purchases of oil from Russia and Iran, which undercut American sanctions on those two countries.
Hopes rose for a breakthrough in talks after U.S. President Donald Trump announced deals with Japan, Indonesia and the Philippines this week.
The U.S. wants China to do two things: Reduce what both the U.S. and the European Union see as excess production capacity in many industries, including steel and electric vehicles. And secondly, to take steps to increase spending by Chinese consumers so the economy relies more on domestic demand and less on exports.
'We could also discuss the elephant in the room, which is this great rebalancing that the Chinese need to do,' Bessent told financial news network CNBC. He said China's share of global manufacturing exports at nearly 30%, 'can't get any bigger, and it should probably shrink.'
China is tackling the same issues — for domestic reasons
The issues are not new, and China has been working to address them for years, more for domestic reasons than to reduce its trade surpluses with the U.S. and other countries.
Bessent's predecessor as treasury secretary, Janet Yellen, made industrial policy a focus of a trip to China last year. She blamed government subsidies for flooding the global market with 'artificially cheap Chinese products.' The European Union, whose top leaders met their Chinese counterparts in Beijing on Thursday, has cited subsidies to justify EU tariffs on electric vehicles made in China.
In the 1980s, the U.S. pressured Japan to boost consumer spending when American manufacturing was overwhelmed by exports from the likes of Toyota and Sony. Economists have long argued that China likewise needs to transform into a more consumer-driven economy. Consumer spending accounts for less than 40% of China's economy, versus close to 70% in the United States and about 54% in Japan.
Chinese leaders have spoken about both factory overcapacity and weak consumer spending as long-term problems and have sought over the past 20 years to find ways to rebalance the economy away from export manufacturing and massive investments in dams, roads, railways and other infrastructure.
Fierce price wars have prompted critical reports in official media saying that companies are 'racing to the bottom,' skimping on quality and even safety to reduce costs.
With strong government support, they've also expanded overseas, where they can charge higher prices but still undercut local competitors, creating a political backlash.
Economists say China needs a consumer-driven economy
All that competition and price cutting has left China battling deflation, or falling prices. When companies receive less for their products, they tend to invest less. That can lead to job cuts and lower wages, sapping business activity and spending power — contrary to the long-term goal of increasing the share of consumer spending in driving overall growth.
To counter that, the government is spending billions on rebates and subsidies for people who trade in their cars or appliances for new ones.
But acknowledging a problem and solving it are two different things. Economists say more fundamental changes are needed to boost consumption and rein in overcapacity. Such changes can only come incrementally over time.
Private Chinese companies and foreign-invested companies create the most jobs, but they've suffered from swings in policy and pressures from the trade war, especially since the pandemic.
Demographic changes are another challenge as China's population shrinks and ages.
Many experts advocate expanding China's social safety net, health insurance, pensions and other support systems, so that people would feel freer to spend rather than save for a medical emergency or retirement.
Yan Se, an economist at Peking University's Guanghua School of Management, warned at a recent forum that deflation will become a long-term issue if China doesn't step up its welfare benefits.
'Chinese people deserve a better life,' he said.
Facing external threats, China wants to be more self-reliant
One possibility, put forward at the same forum by Liu Qiao, the dean of the business school, would be to change incentives for local government officials, rewarding them for raising consumption or household incomes instead of meeting an economic growth target.
He doesn't see that happening nationwide but said it could be tested in a province.
'That would send out a message that China needs a different approach,' he said.
Chinese leader Xi Jinping has made transforming the country into a technology superpower a top priority. It's a goal that has gained urgency as the U.S. has tightened restrictions on China's access to high-end semiconductors and other advanced knowhow.
Output in high-tech manufacturing is growing quickly, adding to potential overcapacity, just as what happened with the government's encouragement of 'green' technologies such as solar panels and wind turbines.
Various industries, including EV makers, have pledged to address the issue, but some local governments are striving to keep money-losing enterprises afloat, reluctant to lose tax revenues and jobs, or to fail to meet economic growth targets.
Going forward, the government is calling for more coordination of economic development polices in fields such as artificial intelligence so that not every province champions the same industry. But government moves to counter the impact of higher tariffs tend to support sectors already in overcapacity, and the share of consumption in the economy has fallen in recent years.
'A sustained improvement in household consumption will require greater reform ambition,' the World Bank said in its most recent update on China's economy.'
___
AP Business Writer Elaine Kurtenbach in Bangkok contributed to this report.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Minerals Technologies Inc. Announces Participation at Upcoming Investor Conferences
Minerals Technologies Inc. Announces Participation at Upcoming Investor Conferences

Yahoo

timea few seconds ago

  • Yahoo

Minerals Technologies Inc. Announces Participation at Upcoming Investor Conferences

NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Minerals Technologies Inc. (NYSE: MTX) ('MTI') today announced its participation at two upcoming investor conferences: August 19, 2025: Seaport Research Partners' Annual Summer Conference (virtual) September 4, 2025: Jefferies' Industrials Conference (in-person in New York, NY) – Douglas T. Dietrich, Chairman and Chief Executive Officer, will present at 3:30pm ET in addition to participating in one-on-ones with individual investors. MTI will be represented by Douglas T. Dietrich, Chairman and Chief Executive Officer, Erik Aldag, Chief Financial Officer, and Lydia Kopylova, Vice President of Investor Relations, at both events. To register and for additional details and presentation materials, please visit MTI's Events & Presentations page. About Minerals Technologies Inc. New York-based Minerals Technologies Inc. is a leading, technology-driven specialty minerals company that develops, produces, and markets a broad range of mineral and mineral-based products, related systems, and services. MTI serves globally a wide range of consumer and industrial markets, including household, food and pharmaceutical, paper, packaging, automotive, construction, and environmental. The company reported global sales of $2.1 billion in 2024. For further information, please visit our website at Investor Relations ContactLydia Media ContactStephanie in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Aggreko Partners With Western Golf Association to Support Scholarships and Veterans for Second Year
Aggreko Partners With Western Golf Association to Support Scholarships and Veterans for Second Year

Yahoo

timea few seconds ago

  • Yahoo

Aggreko Partners With Western Golf Association to Support Scholarships and Veterans for Second Year

As a part of the three-year partnership with WGA, Aggreko continues their support of the Evans Scholars Foundation's college scholarship program Aggreko supports 2025 BMW Championship with power solutions, veteran partnership HOUSTON, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Aggreko, a global leader in energy solutions, announces its continuing partnership with the Western Golf Association (WGA) and Evans Scholars Foundation (ESF). For the second year in a row, the company will serve as the official power provider for WGA-hosted golf championships and a supporter of the ESF's college scholarships for youth caddies. The first partnership event this year is the 2025 BMW Championship on August 12–17 at the Caves Valley Golf Club in Baltimore, Maryland, a PGA TOUR event where Aggreko will also serve as the Official Military Appreciation partner. The energy solutions company will provide both cooling and power technology for the championship event. Along with the WGA partnership, Aggreko is continuing its support of ESF with the Aggreko Power Solutions Evans Scholarship, an award that provides a full tuition and housing college scholarship to a high-achieving youth caddie. The first Aggreko Power Solutions Evans Scholar is Sean Raadsen, a University of Illinois Chicago sophomore studying Aerospace Engineering and an accomplished caddie at the Crystal Lake Country Club in his hometown of Crystal Lake, Illinois. 'Partnering with WGA and ESF has been a great honor for us, and a central part of our youth and veteran outreach,' said Stephen Saal, Vice President of Sales and Marketing at Aggreko North America. 'We are honored to continue supporting WGA events with our advanced energy solutions, as well as supporting the college scholarship program for ESF. We're also pleased to continue our work with the veteran community as the Military Appreciation Partner for the BMW Championship this year.' As the power provider for the BMW Championship, Aggreko will install and operate air conditioners and generators to fulfill the energy needs for the duration of the tournament. The company has also provided power, heating, and cooling services for previous PGA TOUR events, including THE CJ CUP Byron Nelson and the 2024 BMW Championship. Aggreko is also supporting the BMW Championship as Military Appreciation Partner, enabling all active duty, retirees, active reserve, and veterans of any branch of service to receive a complimentary ticket on each day of the championship. Military attendees and their guests will also have access to the Champions Club as the official Military Outpost hospitality tent with complimentary food and beverage on the 14th green for Tuesday and Wednesday's practice rounds. Aggreko's engagement with the BMW Championship continues the company's efforts to support the veteran population. The company actively recruits from the military population, as their expertise makes veterans highly suited to become integral members of Aggreko's workforce. For more information on the Evans Scholarship and how to apply, visit Members of the military can visit the championship's website to secure their complimentary tickets to the event. To learn more about Aggreko's programs supporting veterans and open positions at the company, visit About AggrekoAggreko is a global leader in energy solutions, providing rapidly deployable, modular power and temperature control solutions for however long they're needed. We're highly skilled sector specialists, bringing together our proprietary application know-how and engineering capability to deliver efficient, reliable and sustainable energy solutions. With experience of working in the most demanding environments, we're available for customers when they need us most, from emergency critical services to longer-term energy solutions. We're continually investing in more sustainable products, fuels and services to make greener solutions accessible to customers, helping them wherever they are on their energy transition journey. Founded in 1962, we are headquartered in the UK and employ over 6,800 people worldwide. For more information, please visit our website at Home | Aggreko. Media ContactJustin WilliamsTrevi Communications for Aggrekojustin@ (978) 539-7157‬‬ A photo accompanying this announcement is available at

Phosphoramidite Market Set to Surpass Valuation of US$ 2.44 Billion by 2033
Phosphoramidite Market Set to Surpass Valuation of US$ 2.44 Billion by 2033

Yahoo

timea few seconds ago

  • Yahoo

Phosphoramidite Market Set to Surpass Valuation of US$ 2.44 Billion by 2033

Explosive growth in the oligonucleotide therapeutics pipeline is driving record demand within the phosphoramidite market. Major pharmaceutical companies are responding with significant manufacturing investments to support numerous therapies advancing through late-stage clinical trials and approvals. Chicago, Aug. 07, 2025 (GLOBE NEWSWIRE) -- The global phosphoramidite market was valued at US$ 1.21 billion in 2024 and is expected to reach US$ 2.44 billion by 2033, growing at a CAGR of 8.1% during the forecast period 2025–2033. The global phosphoramidite market is standing at the precipice of a transformative era, propelled by a powerful convergence of breakthroughs in therapeutic sciences and synthetic biology. As the foundational chemical building blocks for synthesizing DNA and RNA, phosphoramidites are central to the next generation of medicine and biotechnological innovation. The burgeoning pipeline of oligonucleotide-based drugs, coupled with accelerating advancements in genetic engineering and diagnostics, is creating a surge in demand that promises robust and sustained growth. Download Sample Pages: This report delineates the potent forces shaping this expansion, offering stakeholders a meticulously researched view of the opportunities unfolding. The sheer volume of investment, the escalating pace of clinical trials, and the strategic realignments within the industry all point towards a dynamic and highly lucrative future for the phosphoramidite market, cementing its role as a critical enabler of 21st-century life sciences. This landscape is not just growing; it is evolving, with new applications and technologies continually broadening its horizons and intensifying its commercial potential. Key Findings Phosphoramidite Market Market Forecast (2033) US$ 2.44 billion CAGR 8.1% Largest Region (2024) North America (40%) By Type DNA Phosphoramidites (37%) By Application Drug Discovery & Development (57%) By End Use Pharmaceutical & Biotechnology Companies (62%) Top Drivers Expanding pipeline of oligonucleotide therapeutics is driving significant market demand. Technological advancements in DNA synthesis are making it more accessible. Rising R&D investments by pharmaceutical and biotechnology companies fuels growth. Top Trends Increasing use of modified phosphoramidites for enhanced drug therapeutic properties. Surging interest in RNA phosphoramidites for developing mRNA therapeutics. The emergence of next-generation sequencing creates new market application frontiers. Top Challenges Manufacturing complexity of producing ultra-pure phosphoramidite reagents. Strict regulatory requirements for therapeutic-grade materials in oligonucleotide synthesis. The limited stability and shelf life of some phosphoramidite reagents. Therapeutic Pipelines Emerge as the Foremost Demand Catalyst for Growth The primary engine powering the phosphoramidite market is the spectacular rise of oligonucleotide therapeutics. These precision medicines, including antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs), are moving from niche applications to mainstream treatment paradigms for genetic and chronic diseases. The scale of this movement is staggering; in November 2024, an estimated 12,500 drugs were in the pre-clinical research phase, a significant portion of which fundamentally rely on oligonucleotide synthesis. This preclinical activity is translating into tangible clinical progress, with over 480 active clinical trials involving oligonucleotide-based drugs recorded in 2023, primarily focused on ASO and siRNA modalities. The U.S. Food and Drug Administration (FDA) is endorsing this wave of innovation, having approved two new oligonucleotide therapeutics, imetelstat and olezarsen, in 2024 alone. The commercial outlook is equally bright, with several existing RNAi and ASO therapies like Amvuttra and Leqvio projected to achieve blockbuster status, exceeding $1 billion in annual revenue by 2030. Regulatory Endorsements and Anticipated Approvals Solidify Market Confidence The positive trajectory of the phosphoramidite market is further reinforced by a supportive regulatory environment and a clear pipeline of upcoming therapies. In a significant move in June 2024, the U.S. FDA accepted the New Drug Application for Fitusiran, a promising RNAi therapeutic designed to treat hemophilia. This signals continued confidence in the technology's potential. Looking ahead, the momentum is set to continue, with industry analysts forecasting that at least three more small nucleic acid therapies are on track for approval by the end of 2025. This steady stream of approvals not only expands the addressable patient population but also de-risks future investment in the underlying technologies and supply chains. This clear and predictable pathway to commercialization provides a stable foundation for the entire phosphoramidite market, assuring suppliers of long-term demand from a growing portfolio of life-changing medicines. The Synthetic Biology Revolution Creates New Frontiers for Demand Beyond therapeutics, the parallel explosion in synthetic biology is creating a vast and rapidly expanding new frontier for phosphoramidite consumption. This field, which focuses on engineering biological systems for novel purposes, is fundamentally dependent on high-quality, custom-synthesized DNA. The financial commitment to this sector is a testament to its potential, with private funding for synthetic biology startups projected to surge past the $5 billion mark by the end of 2024. This capital is fueling innovation across numerous applications, including personalized medicine, which itself is on track to become a major economic force, expected to generate $12 billion in revenue by the close of 2024. Technological advancements are enabling this growth; in a key development from July 2024, Ansa Biotechnologies launched its next-generation clonal DNA and DNA fragments, providing researchers with sequence-perfect DNA up to 600 base pairs long, a process that will invariably drive demand for the high-purity phosphoramidites required for such precision. North America and Europe: The Established Hubs of Innovation Geographically, North America asserted its leadership in the global phosphoramidite market in 2024, commanding a dominant 39.30% share of the landscape. This preeminence is fueled by the region's dense concentration of major pharmaceutical corporations, pioneering biotechnology firms, and world-class academic research institutions, all heavily invested in life sciences R&D. The United States market, a powerhouse within the region, was individually valued at an impressive $487.9 million in 2024, reflecting its significant consumption of phosphoramidites for both therapeutic development and fundamental research. Across the Atlantic, the United Kingdom emerged as the key revenue leader in the European market in 2024, a position solidified by substantial government investment in research and development initiatives that directly and indirectly spur demand for synthesis reagents. Asia-Pacific's Ascent Signals a Global Shift in Market Dynamics While North America currently leads, the most dynamic growth story is unfolding in the Asia-Pacific (APAC) region. Forecasts indicate that APAC is on a rapid upward trajectory, projected to become the fastest-growing region and poised to capture over 25.2% of the global market share in 2025. This accelerated growth is driven by increasing government and private sector investment in biotechnology infrastructure, a burgeoning pharmaceutical manufacturing sector, and a growing pool of scientific talent. Countries across the region are actively fostering innovation ecosystems, leading to a significant uptick in research activities related to genomics, drug discovery, and diagnostics. This regional expansion represents a critical diversification of the global phosphoramidite market, creating new logistical networks and competitive pressures that will reshape the industry's future. DNA Phosphoramidites Dominate, but RNA Synthesis Shows Fastest Growth A granular look at market segmentation reveals distinct trends by type and application. In 2024, DNA phosphoramidites stood as the dominant market segment, valued at a substantial $642.8 million. This is a direct reflection of their widespread use in diagnostics, PCR applications, and DNA sequencing. However, the segment poised for the most rapid expansion is RNA phosphoramidites, a trend directly linked to the burgeoning field of RNA therapeutics and the development of mRNA vaccines. When viewed through the lens of application, drug discovery and development was the undisputed leader in 2024, accounting for a commanding 54.14% of the total revenue share. This highlights the immense resources being poured into creating new oligonucleotide-based drugs, making it the primary value driver for the entire phosphoramidite market. Pharmaceutical Giants and Academia Drive End-User Consumption Analyzing the end-user landscape, pharmaceutical and biotechnology companies were the foremost consumers in 2024, commanding an overwhelming 61.88% of the market. This segment's dominance is projected to intensify, with forecasts suggesting it will grow into a $1.3 billion powerhouse by 2034. These commercial entities are at the forefront of translating scientific discoveries into marketable products, requiring industrial-scale quantities of phosphoramidites. Concurrently, academic and government research institutes remain a vital pillar of the phosphoramidite market, responsible for 41.3% of the revenue in 2024. These institutions conduct the foundational research that fuels the therapeutic pipeline. Within the crucial application of synthetic biology, genome engineering was the leading technology in 2024, holding a 33.86% share and serving as a key consumer of phosphoramidites for advanced genetic modifications. Strategic Investments and Collaborations Are Reshaping the Competitive Arena The industry's immense potential is attracting significant strategic investment and fostering collaborations designed to accelerate innovation. A landmark deal in June 2024 saw pharmaceutical giant GSK plc acquire Elsie Biotechnologies for $50 million, a strategic move explicitly aimed at enhancing its internal capabilities for developing sophisticated oligonucleotide-based medicines. This acquisition signals a trend of major players securing proprietary technology to gain a competitive edge. Collaborative efforts are also shaping the future of therapeutics in the phosphoramidite market. In February 2025, Biogen and Stoke Therapeutics, Inc., announced a major research collaboration to jointly develop and commercialize Zorevunersen, an investigational ASO aimed at treating Dravet syndrome. These partnerships pool resources and expertise, de-risking development and accelerating the journey of new drugs from the laboratory to the clinic, ensuring a robust and collaborative future for drug development. Request Region or Segment-Specific Customization: Regulatory Guidance and Quality Standards Ensure a Stable Future Outlook A maturing regulatory landscape and an industry-wide focus on quality are providing a stable foundation for the sustained growth of the phosphoramidite market. Recognizing the need for clarity, the FDA released a final guidance document in June 2024 titled "Clinical Pharmacology Considerations for the Development of Oligonucleotide Therapeutics," providing a clear roadmap for drug developers. Furthering this trend, in January 2025, key industry stakeholders began advocating for the FDA to harmonize its guidances with international standards, a move that would streamline global drug development and market access. At the product level, the pursuit of purity remains paramount. This was underscored by a 2024 patent awarded to Wave Life Sciences for an advanced synthesis method capable of achieving purity levels of 95% or more, highlighting the critical importance of quality for therapeutic efficacy and safety. This collective focus on standardization and quality excellence is crucial for building stakeholder confidence and ensuring the long-term integrity of the global supply chain. Global Phosphoramidite Market Major Players: Bioneer Biosynth Ltd BOC Sciences Creative Biolabs, Inc. Danaher Corporation Hongene Biotech Corporation Lumiprobe Corporation PolyOrg, Inc. QIAGEN N.V. Thermo Fisher Scientific Inc. Tokyo Chemical Industry (India) Pvt. Ltd. TriLink BioTechnologies Other Prominent Players Key Market Segmentation: By Type DNA Phosphoramidites RNA Phosphoramidites Labeled Phosphoramidites Modifier Phosphoramidites Others By Application Drug Discovery & Development Diagnostics Development Others By End Use Pharmaceutical & Biotechnology Companies Academic & Research Institutes Others By Region North America Europe Asia Pacific Middle East Africa South America Want Clarity on Report Coverage? Schedule a Quick Demo Call: About Astute Analytica Astute Analytica is a global market research and advisory firm providing data-driven insights across industries such as technology, healthcare, chemicals, semiconductors, FMCG, and more. We publish multiple reports daily, equipping businesses with the intelligence they need to navigate market trends, emerging opportunities, competitive landscapes, and technological advancements. With a team of experienced business analysts, economists, and industry experts, we deliver accurate, in-depth, and actionable research tailored to meet the strategic needs of our clients. At Astute Analytica, our clients come first, and we are committed to delivering cost-effective, high-value research solutions that drive success in an evolving marketplace. Contact Us:Astute AnalyticaPhone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World)For Sales Enquiries: sales@ Follow us on: LinkedIn | Twitter | YouTube CONTACT: Contact Us: Astute Analytica Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World) For Sales Enquiries: sales@ Website:

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store